These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

91 related articles for article (PubMed ID: 19119512)

  • 1. [Application of rifabutin, a rifamycin-group antibiotic, to patients with tuberculosis].
    Kekkaku; 2008 Oct; 83(10):679. PubMed ID: 19119512
    [No Abstract]   [Full Text] [Related]  

  • 2. Clinical use of rifabutin, a rifamycin-class antibiotic, for the treatment of tuberculosis (A supplement to the 2008 revision of "Standards for tuberculosis care").
    ;
    Kekkaku; 2011 Jan; 86(1):43. PubMed ID: 21401006
    [No Abstract]   [Full Text] [Related]  

  • 3. [Pharmacoeconomic model of the use of rifabutin in new cases of pulmonary tuberculosis].
    Mednikov BL; Plaksin DI; Piiavskiĭ SA
    Probl Tuberk; 2002; (9):13-7. PubMed ID: 12524980
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Rifamycin treatment of tuberculosis in a patient receiving atenolol: less interaction with rifabutin than with rifampin.
    Goldberg SV; Hanson D; Peloquin CA
    Clin Infect Dis; 2003 Aug; 37(4):607-8. PubMed ID: 12905149
    [No Abstract]   [Full Text] [Related]  

  • 5. [Skin discoloration].
    Ouzaid I; Lepeule R; Finke E; Pacanowski J; Cochen V; Tiev K; Fardet L; Cabane J; Kettaneh A
    Rev Med Interne; 2006 Oct; 27(10):787-8. PubMed ID: 16949705
    [No Abstract]   [Full Text] [Related]  

  • 6. Pharmacokinetic evaluation of rifabutin in combination with lopinavir-ritonavir in patients with HIV infection and active tuberculosis.
    Boulanger C; Hollender E; Farrell K; Stambaugh JJ; Maasen D; Ashkin D; Symes S; Espinoza LA; Rivero RO; Graham JJ; Peloquin CA
    Clin Infect Dis; 2009 Nov; 49(9):1305-11. PubMed ID: 19807276
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Intermittent antimycobacterial dosage correction.
    Slain D
    Clin Infect Dis; 2001 Jan; 32(2):321-2; author reply 323. PubMed ID: 11170930
    [No Abstract]   [Full Text] [Related]  

  • 8. [Rifabutin].
    Enferm Infecc Microbiol Clin; 1996 May; 14(5):329-30. PubMed ID: 8744377
    [No Abstract]   [Full Text] [Related]  

  • 9. Pharmacokinetics and dosage adjustment of rifabutin in a haemodialysis patient.
    Bassilios N; Launay-Vacher V; Hamani AA; Masias L; Peytavin G; Fau JB; Deray G
    Nephrol Dial Transplant; 2002 Mar; 17(3):531-2. PubMed ID: 11865118
    [No Abstract]   [Full Text] [Related]  

  • 10. A regimen containing rifabutin for the treatment of tuberculosis in patients intolerant to rifampin.
    Tattevin P; Revest M; Dupont M; Arvieux C; Michelet C
    Clin Infect Dis; 2003 Jan; 36(1):127-8. PubMed ID: 12491218
    [No Abstract]   [Full Text] [Related]  

  • 11. Rifabutin.
    Tuberculosis (Edinb); 2008 Mar; 88(2):145-7. PubMed ID: 18486056
    [No Abstract]   [Full Text] [Related]  

  • 12. Concomitant use of voriconazole and rifabutin in a patient with multiple infections.
    Schwiesow JN; Iseman MD; Peloquin CA
    Pharmacotherapy; 2008 Aug; 28(8):1076-80. PubMed ID: 18657024
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Drug-induced lupus associated with rifabutin: a literature review.
    Anyimadu H; Saadia N; Mannheimer S
    J Int Assoc Provid AIDS Care; 2013; 12(3):166-8. PubMed ID: 23442494
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Therapeutic efficacy of liposomal rifabutin in a Mycobacterium avium model of infection.
    Gaspar MM; Neves S; Portaels F; Pedrosa J; Silva MT; Cruz ME
    Antimicrob Agents Chemother; 2000 Sep; 44(9):2424-30. PubMed ID: 10952590
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Pharmacokinetic and pharmacodynamic considerations of rifamycin antibiotics for the treatment of tuberculosis.
    Sekaggya-Wiltshire C; Dooley KE
    Expert Opin Drug Metab Toxicol; 2019 Aug; 15(8):615-618. PubMed ID: 31339806
    [No Abstract]   [Full Text] [Related]  

  • 16. Therapeutic drug monitoring of antimycobacterial drugs in patients with both tuberculosis and advanced human immunodeficiency virus infection.
    Holland DP; Hamilton CD; Weintrob AC; Engemann JJ; Fortenberry ER; Peloquin CA; Stout JE
    Pharmacotherapy; 2009 May; 29(5):503-10. PubMed ID: 19397460
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Evaluation of high- versus standard-dose rifampin in Indonesian patients with pulmonary tuberculosis.
    Ruslami R; Nijland H; Aarnoutse R; Alisjahbana B; Soeroto AY; Ewalds S; van Crevel R
    Antimicrob Agents Chemother; 2006 Feb; 50(2):822-3. PubMed ID: 16436757
    [No Abstract]   [Full Text] [Related]  

  • 18. [Organization of antitubercular chemotherapy in Morocco].
    Bennis A; Iraqu G; Abdellaoui A; Bouzekri M; Bartal M
    Maghrib Tibbi; 1980 Oct; 2(3):247-54. PubMed ID: 7230886
    [No Abstract]   [Full Text] [Related]  

  • 19. Rifamycin-resistant Mycobacterium tuberculosis in the highly active antiretroviral therapy era: a report of 3 relapses with acquired rifampin resistance following alternate-day rifabutin and boosted protease inhibitor therapy.
    Jenny-Avital ER; Joseph K
    Clin Infect Dis; 2009 May; 48(10):1471-4. PubMed ID: 19368504
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Hacking into the granuloma: could antibody antibiotic conjugates be developed for TB?
    Ekins S
    Tuberculosis (Edinb); 2014 Dec; 94(6):715-6. PubMed ID: 25287628
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.